专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060100228A1 Cannabinoid receptor ligands 失效
标题翻译：大麻素受体配体
公开(公告)号：US20060100228A1
公开(公告)日：2006-05-11
申请号：US11157510
申请日：2005-06-21
申请人： Bandarpalle Shankar , Eric Gilbert , Razia Rizvi , Chunli Huang , Joseph Kozlowski , Stuart McCombie , Neng-Yang Shih
发明人： Bandarpalle Shankar , Eric Gilbert , Razia Rizvi , Chunli Huang , Joseph Kozlowski , Stuart McCombie , Neng-Yang Shih
IPC分类号： A61K31/4747 , A61K31/46 , A61K31/405 , C07D455/02 , C07D403/02
CPC分类号： C07D221/20 , C07D209/52 , C07D401/12 , C07D471/08
摘要： Compounds of Formula I: and/or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions containing such compounds exhibit anti-inflammatory and immunomodulatory activity, and can be effective in treating cancer and inflammatory, immunomodulatory or respiratory diseases or conditions.
摘要翻译：式I化合物和/或其药学上可接受的盐，溶剂化物或前药，或含有这些化合物的药物组合物表现出抗炎和免疫调节活性，并且可有效治疗癌症和炎症，免疫调节或呼吸系统疾病或病症。

2. 发明授权

US07750158B2 Cannabinoid receptor ligands 失效
标题翻译：大麻素受体配体
公开(公告)号：US07750158B2
公开(公告)日：2010-07-06
申请号：US11157510
申请日：2005-06-21
申请人： Bandarpalle B. Shankar , Eric Gilbert , Razia K. Rizvi , Chunli Huang , Joseph A. Kozlowski , Stuart McCombie , Neng-Yang Shih
发明人： Bandarpalle B. Shankar , Eric Gilbert , Razia K. Rizvi , Chunli Huang , Joseph A. Kozlowski , Stuart McCombie , Neng-Yang Shih
IPC分类号： C07D221/00 , A61K31/44
CPC分类号： C07D221/20 , C07D209/52 , C07D401/12 , C07D471/08
摘要： Compounds of Formula I: and/or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions containing such compounds exhibit anti-inflammatory and immunomodulatory activity, and can be effective in treating cancer and inflammatory, immunomodulatory or respiratory diseases or conditions.
摘要翻译：式I化合物和/或其药学上可接受的盐，溶剂化物或前药，或含有这些化合物的药物组合物表现出抗炎和免疫调节活性，并且可有效治疗癌症和炎症，免疫调节或呼吸系统疾病或病症。

3. 发明申请

US20050182095A1 Piperdine derivatives useful as CCR3 antagonists 失效
标题翻译：哌啶衍生物可用作CCR3拮抗剂
公开(公告)号：US20050182095A1
公开(公告)日：2005-08-18
申请号：US11049460
申请日：2005-02-02
申请人： Pauline Ting , Jianhua Cao , Youhao Dong , Eric Gilbert , Ying Huang , Joseph Kelly , Stuart McCombie , Neng-Yang Shih
发明人： Pauline Ting , Jianhua Cao , Youhao Dong , Eric Gilbert , Ying Huang , Joseph Kelly , Stuart McCombie , Neng-Yang Shih
IPC分类号： A61K31/444 , A61K31/4545 , A61K31/4709 , C07D211/18 , C07D211/58 , C07D401/04 , C07D401/14 , C07D413/14 , C07D471/04 , C07D41/14
CPC分类号： C07D401/14 , C07D211/18 , C07D211/58 , C07D401/04 , C07D471/04
摘要： The use of CCR3 antagonists of the formula I or a pharmaceutically acceptable salt thereof for the treatment of asthma is disclosed, as well as novel compounds of the formula II, pharmaceutical compositions comprising them, and their use in the treatment of asthma, wherein R, Ra, X, Xa, R1, R2, R2a, R14, R14a, R16 and n are as defined in the specification.
摘要翻译：公开了使用式I的CCR3拮抗剂或其药学上可接受的盐治疗哮喘，以及式II的新型化合物，包含它们的药物组合物及其在治疗哮喘中的用途，其中R， X 1，X 1，X 2，...，R 2，R 2，R 2， >，R 14，R 14a，R 16和n如说明书中所定义。

4. 发明授权

US07384944B2 Piperazine derivatives useful as CCR5 antagonists 有权
标题翻译：哌嗪衍生物可用作CCR5拮抗剂
公开(公告)号：US07384944B2
公开(公告)日：2008-06-10
申请号：US10668862
申请日：2003-09-23
申请人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Elizabeth M. Smith , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Mark A. Laughlin , Eric Gilbert , Marc A. Labroli
发明人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Elizabeth M. Smith , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Mark A. Laughlin , Eric Gilbert , Marc A. Labroli
IPC分类号： A61K31/497
CPC分类号： C07D401/06 , A61K31/496 , A61K45/06 , C07D211/58 , C07D401/10 , C07D401/12 , C07D405/12 , C07D409/06 , C07D413/06 , A61K2300/00
摘要： The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要翻译：使用下式的CCR5拮抗剂或其药学上可接受的盐，其中R是任选取代的苯基，吡啶基，噻吩基或萘基; R 1是氢或烷基; R 2是取代的苯基，取代的杂芳基，萘基，芴基，二苯基甲基或任选取代的苯基或杂芳基 - 烷基; R 3是氢，烷基，烷氧基烷基，环烷基，环烷基烷基或任选取代的苯基，苯基烷基，萘基，萘基烷基，杂芳基或杂芳基烷基; R 4，R 5和R 7是氢或烷基; R 6是氢，烷基或链烯基; 公开了用于治疗HIV，实体器官移植排斥，移植物抗宿主病，关节炎，类风湿性关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化的新型化合物，以及包含它们的药物组合物，以及本发明的CCR5拮抗剂与可用于治疗HIV的抗病毒剂或可用于治疗炎性疾病的药剂的组合。

5. 发明申请

US20060241121A1 Substituted piperazines as CB1 antagonists 失效
标题翻译：取代的哌嗪作为CB1拮抗剂
公开(公告)号：US20060241121A1
公开(公告)日：2006-10-26
申请号：US11292264
申请日：2005-12-01
申请人： William Greenlee , Jay Weinstein , Eric Gilbert , Michael Miller , Jack Scott , Andrew Stamford
发明人： William Greenlee , Jay Weinstein , Eric Gilbert , Michael Miller , Jack Scott , Andrew Stamford
IPC分类号： A61K31/496 , A61K31/495 , C07D403/04 , C07D241/04
CPC分类号： C07D241/04 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/06 , C07D403/10 , C07D403/12 , C07D405/04 , C07D405/06 , C07D405/08 , C07D405/12 , C07D409/04 , C07D409/06 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D417/06 , C07D417/10
摘要： Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.
摘要翻译：式（I）化合物或其药学上可接受的盐，溶剂合物或酯可用于治疗由CB1受体介导的疾病或病症，例如代谢综合征和肥胖症，神经炎症性疾病，认知障碍精神病，成瘾（如戒烟），胃肠道疾病和心血管疾病。

6. 发明申请

US20060064245A1 Vehicle collision shield 有权
标题翻译：车辆碰撞盾
公开(公告)号：US20060064245A1
公开(公告)日：2006-03-23
申请号：US10945373
申请日：2004-09-20
申请人： Eric Gilbert
发明人： Eric Gilbert
IPC分类号： G08G1/16
CPC分类号： G01S13/931 , B60T7/22 , G01S15/93 , G01S2013/9346 , G01S2013/9353 , G01S2013/9382 , G08G1/16 , G08G1/165 , G08G5/00
摘要： In the present disclosure, systems and methods for preventing collisions between a ground services vehicle and other objects are described. In one embodiment, a system includes a digital three dimensional map of the outer dimensions of the ground vehicle, a micro radar device, a comparator, and an indicator. The micro radar device is secured to the ground vehicle. A comparator signals when an object is within a predetermined envelope around the outer dimensions of the ground vehicle. The comparator receives signals from the micro radar device, and includes dimension data from the three dimensional map. The indicator is responsive to the signal from the comparator. The indicator alerts of possible and pending collision when the predetermined envelope is breached. The indicator may also activate a brake mechanism to stop the ground vehicle. Methods for carrying out the invention by sensing a breach of the envelope and stopping the vehicle are also disclosed.
摘要翻译：在本公开中，描述了用于防止地面服务车辆与其他物体之间的碰撞的系统和方法。在一个实施例中，系统包括地面车辆的外部尺寸的数字三维地图，微型雷达装置，比较器和指示器。微型雷达装置固定在地面车辆上。当对象在地面车辆的外部尺寸周围处于预定的包围内时，比较器发出信号。比较器从微型雷达装置接收信号，并包括来自三维图的尺寸数据。指示器响应来自比较器的信号。当预定的信封被破坏时，指示器警报可能的和未决的碰撞。指示器还可以启动制动机构以停止地面车辆。还公开了通过感测泄漏信封和停止车辆来实施本发明的方法。

7. 发明授权

US06391865B1 Piperazine derivatives useful as CCR5 antagonists 有权
标题翻译：哌嗪衍生物可用作CCR5拮抗剂
公开(公告)号：US06391865B1
公开(公告)日：2002-05-21
申请号：US09562814
申请日：2000-05-01
申请人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Elizabeth M. Smith , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Eric Gilbert , Marc A. Labroli
发明人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Elizabeth M. Smith , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Eric Gilbert , Marc A. Labroli
IPC分类号： A01N5500
CPC分类号： A61K31/496 , A61K45/06 , C07D211/58 , C07D401/06 , C07D401/10 , C07D401/12 , C07D405/12 , C07D409/06 , C07D413/06 , A61K2300/00
摘要： The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要翻译：使用式5的CCR5拮抗剂或其药学上可接受的盐，其中R是任选取代的苯基，吡啶基，噻吩基或萘基; R 1是氢或烷基; R 2是取代的苯基，取代的杂芳基，萘基，芴基，二苯基甲基或任选取代的苯基 - R 4是氢或烷基; R 6是氢，烷基或链烯基; R 4是氢或烷基; R 3是氢，烷基或烷氧基烷基，公开了用于治疗HIV，实体器官移植排斥，移植物抗宿主病，关节炎，类风湿性关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化的新型化合物，以及包含它们的药物组合物，以及本发明的CCR5拮抗剂与可用于治疗HIV的抗病毒剂或可用于治疗炎性疾病的药剂的组合。

8. 发明申请

US20080188485A1 PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS 有权
标题翻译：哌啶衍生物作为CCR5拮抗剂有用
公开(公告)号：US20080188485A1
公开(公告)日：2008-08-07
申请号：US12055900
申请日：2008-03-26
申请人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Elizabeth M. Smith , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Mark A. Laughlin , Eric Gilbert , Marc A. Labroli
发明人： Bahige M. Baroudy , John W. Clader , Hubert B. Josien , Stuart W. McCombie , Brian A. McKittrick , Michael W. Miller , Bernard R. Neustadt , Anandan Palani , Elizabeth M. Smith , Ruo Steensma , Jayaram R. Tagat , Susan F. Vice , Mark A. Laughlin , Eric Gilbert , Marc A. Labroli
IPC分类号： A61K31/496 , A61P1/00 , A61P19/02
CPC分类号： C07D401/06 , A61K31/496 , A61K45/06 , C07D211/58 , C07D401/10 , C07D401/12 , C07D405/12 , C07D409/06 , C07D413/06 , A61K2300/00
摘要： The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroarylalkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
摘要翻译：使用下式的CCR5拮抗剂或其药学上可接受的盐，其中R是任选取代的苯基，吡啶基，噻吩基或萘基; R 1是氢或烷基; R 2是取代的苯基，取代的杂芳基，芴基，二苯甲基或任选取代的苯基或杂芳基烷基; R 3是氢，烷基，烷氧基烷基，环烷基，环烷基烷基或任选取代的苯基，苯基烷基，萘基，萘基烷基，杂芳基或杂芳基烷基; R 4，R 5和R 7是氢或烷基; R 6是氢，烷基或链烯基; 公开了用于治疗HIV，实体器官移植排斥，移植物抗宿主病，关节炎，类风湿性关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化的新型化合物，以及包含它们的药物组合物，以及本发明的CCR5拮抗剂与可用于治疗HIV的抗病毒剂或可用于治疗炎性疾病的药剂的组合。

9. 发明申请

US20070203183A1 Diaryl piperidines as CB1 modulators 审中-公开
标题翻译：二芳基哌啶作为CB1调节剂
公开(公告)号：US20070203183A1
公开(公告)日：2007-08-30
申请号：US11652227
申请日：2007-01-11
申请人： Jack Scott , Jay Weinstein , Michael Miller , Andrew Stamford , Eric Gilbert , Yan Xia , William Greenlee , Sarah Li
发明人： Jack Scott , Jay Weinstein , Michael Miller , Andrew Stamford , Eric Gilbert , Yan Xia , William Greenlee , Sarah Li
IPC分类号： A61K31/454 , C07D211/54 , A61K31/445 , C07D401/02
CPC分类号： C07D211/18 , C07D211/22 , C07D211/26 , C07D211/28 , C07D211/30 , C07D211/32 , C07D211/58 , C07D211/60 , C07D211/76 , C07D401/04 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/06 , C07D471/10
摘要： A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome (e.g., obesity, waist circumference, lipid profile, and insulin sensitivity), neuroinflammatory disorders, cognitive disorders, psychosis, addictive behavior, gastrointestinal disorders, and cardiovascular conditions.
摘要翻译：具有式（I）的通式结构的化合物或其药学上可接受的盐，溶剂化物或酯可用于治疗疾病，病症或病症如代谢综合征（例如，肥胖，腰围，脂质分布和胰岛素敏感性），神经炎症性疾病，认知障碍，精神病，成瘾行为，胃肠道疾病和心血管疾病。

10. 发明申请

US20060132106A1 System and method for regenerative burn-in 审中-公开
标题翻译：再生老化的系统和方法
公开(公告)号：US20060132106A1
公开(公告)日：2006-06-22
申请号：US11287580
申请日：2005-11-23
申请人： Michael Lucas , Eric Gilbert
发明人： Michael Lucas , Eric Gilbert
IPC分类号： G05F1/577
CPC分类号： G01R31/2879 , G01R31/2849 , G01R31/2891 , G01R31/40 , H02M3/3378
摘要： A regenerative load that includes an input configured to draw a specified current and an output configured to provide an output voltage and current is described. The regenerative load configured to maintain the output voltage to cause the regenerative load to draw the specified current from the unit under test. The output of the regenerative load is provided back to the input of the unit under test. The input current or voltage can be AC, DC, or a combination of AC and DC. The output current or voltage can be AC, DC, or a combination of AC and DC. In one embodiment, a thermal barrier is provided between a test chamber and a load chamber to allow converters under test to be operated at a test temperature while the regenerative loads are operated at a desired operational temperature.
摘要翻译：描述了包括被配置为绘制指定电流的输入和被配置为提供输出电压和电流的输出的再生负载。配置为保持输出电压以使再生负载从被测单元中抽出指定电流的再生负载。再生负载的输出返回到被测单元的输入端。输入电流或电压可以是AC，DC或AC和DC的组合。输出电流或电压可以是AC，DC或AC和DC的组合。在一个实施例中，在测试室和负载室之间提供热障，以允许被测试转换器在测试温度下操作，同时再生负载在期望的操作温度下操作。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式